Sign In
Buy LGND
$287.54
-8.75 (-2.95%)
At Close: Jul 31, 2026
4 Biotech Stocks to Consider for Your Portfolio in 2023
01:00pm, Tuesday, 21'st Mar 2023
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KAL
How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%
11:30am, Friday, 17'th Mar 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 49.1% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positiv
Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up
09:02am, Thursday, 23'rd Feb 2023
Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news.
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates
09:49pm, Wednesday, 22'nd Feb 2023
Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals, Inc. (LGND) Q4 2022 Earnings Call Transcript
09:41pm, Wednesday, 22'nd Feb 2023
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND ) Q4 2022 Earnings Conference Call February 22, 2023 4:00 PM ET Company Participants Simon Latimer - Head, IR Todd Davis - CEO Tavo Espinoza - CFO Matthew Kor
LGND vs. INCY: Which Stock Should Value Investors Buy Now?
12:47pm, Thursday, 29'th Dec 2022
LGND vs. INCY: Which Stock Is the Better Value Option?
Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?
11:17am, Monday, 19'th Dec 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
LGND or GMAB: Which Is the Better Value Stock Right Now?
12:48pm, Tuesday, 13'th Dec 2022
LGND vs. GMAB: Which Stock Is the Better Value Option?
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
12:47pm, Tuesday, 08'th Nov 2022
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.
Ligand Pharmaceuticals, Inc. (LGND) Q3 2022 - Earnings Call Transcript
09:50pm, Monday, 07'th Nov 2022
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew Korenberg - President
Ligand Pharmaceuticals (LGND) Misses Q3 Earnings Estimates
06:56pm, Monday, 07'th Nov 2022
Ligand (LGND) delivered earnings and revenue surprises of -8.89% and 71.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ligand to Report Third Quarter Financial Results on November 7
06:00pm, Wednesday, 26'th Oct 2022
SAN DIEGO--(BUSINESS WIRE)--Ligand to Report Third Quarter Financial Results on November 7
LGND vs. RGEN: Which Stock Is the Better Value Option?
12:48pm, Friday, 21'st Oct 2022
LGND vs. RGEN: Which Stock Is the Better Value Option?
Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?
12:48pm, Wednesday, 07'th Sep 2022
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
Ligand Pharmaceuticals, Inc. (LGND) CEO John Higgins on Q2 2022 Results - Earnings Call Transcript
09:08pm, Monday, 08'th Aug 2022
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO & Executive Director Matthew Kor
